Scientific Reports (Aug 2024)

Examining the clinical and genetic spectrum of maturity-onset diabetes of the young (MODY) in Iran

  • Sara Asgarian,
  • Hossein Lanjanian,
  • Shiva Rahimipour Anaraki,
  • Farzad Hadaegh,
  • Maryam Moazzam-Jazi,
  • Leila Najd-Hassan-Bonab,
  • Sajedeh Masjoudi,
  • Asiyeh Sadat Zahedi,
  • Maryam Zarkesh,
  • Bita Shalbafan,
  • Mahdi Akbarzadeh,
  • Sahand Tehrani Fateh,
  • Davood Khalili,
  • Amirabbas Momenan,
  • Narges Sarbazi,
  • Mehdi Hedayati,
  • Fereidoun Azizi,
  • Maryam S. Daneshpour

DOI
https://doi.org/10.1038/s41598-024-70864-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Maturity-onset diabetes of the young (MODY) is an uncommon monogenic type of diabetes mellitus. Detecting genetic variants for MODY is a necessity for precise diagnosis and treatment. The majority of MODY genetic predisposition has been documented in European populations and a lack of information is present in Iranians which leads to misdiagnosis as a consequence of defects in unknown variants. In this study, using genetic variant information of 20,002 participants from the family-based TCGS (Tehran Cardiometabolic Genetic Study) cohort, we evaluated the genetic spectrum of MODY in Iran. We concentrated on previously discovered MODY-causing genes. Genetic variants were evaluated for their pathogenicity. We discovered 6 variants that were previously reported in the ClinVar as pathogenic/likely pathogenic (P/LP) for MODY in 45 participants from 24 families (INS in 21 cases, GCK in 13, HNF1B in 8, HNF4A, HNF1A, and CEL in 1 case). One potential MODY variant with Uncertain Risk Allele in ClinVar classification was also identified, which showed complete disease penetrance (100%) in four subjects from one family. This is the first family-based study to define the genetic spectrum and estimate the prevalence of MODY in Iran. The discovered variants need to be investigated by additional studies.

Keywords